Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
AssigneesMount Sinai School of Medicine, The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsPeter Palese, Adolfo Garcia-Sastre, Nicholas P. Restifo
Life of this patent
Estimating the term…
Abstract
The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.
Claims13
A method of inducing an immune response against a tumor-associated antigen or an epitope of a tumor-associated antigen in a patient, comprising administering to a patient in need thereof an immunogenic composition consisting essentially of an effective amount of a recombinant influenza virus and a pharmaceutically acceptable carrier, wherein the genome of the virus contains a region encoding the tumor-associated antigen or the epitope of a tumor-associated antigen.
Dependencies are inferred from the claim text.